

## **10-Minute Tutorials**

OHDSI Community Call June 8, 2021 • 11 am ET



## **Upcoming OHDSI Community Calls**

Date	Topic	
June 8	10-Minute Tutorials: PHOEBE, Cohort Diagnostics, ATC Hierarchy	
June 15	Professional Development Breakouts: Clinical Epidemiology, Information/Data Management,	
	Open-Source Software Development, Statistical Methods	
June 22	Community Presentations: New Developments within OHDSI	
June 29	Focus Topic: EUMEAUS (Evaluating Use of Methods for Adverse Event Under Surveillance	
July 6	Meet & Greet New OHDSI Collaborators	
July 13	Focus Topic: PROTEUS	
July 20	Workgroup Updates	
July 27	Visualization Challenge	



## **Upcoming OHDSI Community Calls**

Date	Topic	
June 8	10-Minute Tutorials: PHOEBE, Cohort Diagnostics, ATC Hierarchy	
June 15	Professional Development Breakouts: Clinical Epidemiology, Information/Data Management,  Open-Source Software Development, Statistical Methods	
June 22	Community Presentations: New Developments within OHDSI	
June 29	Focus Topic: EUMEAUS (Evaluating Use of Methods for Adverse Event Under Surveillance	
July 6	Meet & Greet New OHDSI Collaborators	
July 13	Focus Topic: PROTEUS	
July 20	Workgroup Updates	
July 27	Visualization Challenge	





## **June 15: Community Breakouts**

**Theme - Professional Development** 

Clinical Epidemiology Information/
Data Management

Open-Source Software Development

Statistical Methods





## Three Stages of The Journey

# Where Have We Been? Where Are We Now? Where Are We Going?





## **OHDSI Shoutouts!**



Congratulations to Gyu Lee Kim, Yu Hyeon Yi, Hye Rim Hwang, Jinmi Kim, Youngmin Park, Yun Jin Kim, Jeong Gyu Lee, Young Jin Tak, Seung Hun Lee, Sang Yeoup Lee, Youn Hye Cho, Eun Ju Park, and Youngin Lee for this recent study "The Risk of Osteoporosis and Osteoporotic Fracture Following the Use of Irritable Bowel **Syndrome Medical Treatment: An Analysis Using the OMOP CDM** Database" that was posted last week in the Journal of Clinical Medicine.



Open Access Article

The Risk of Osteoporosis and Osteoporotic Fracture Following the Use of Irritable Bowel Syndrome Medical Treatment: An Analysis Using the OMOP CDM Database

```
by Ogyu Lee Kim <sup>1,2</sup> , O Yu Hyeon Yi <sup>1,2</sup>, O Hye Rim Hwang <sup>1,2</sup> , O Jinmi Kim <sup>3</sup> , O Youngmin Park <sup>4</sup> , O Yun Jin Kim <sup>1,2</sup> , O Jeong Gyu Lee <sup>1,2</sup> , O Young Jin Tak <sup>1,2</sup> , O Seung Hun Lee <sup>1,2</sup> , Sang Yeoup Lee <sup>2,5</sup> , O Youn Hye Cho <sup>2,5</sup> , O Eun Ju Park <sup>2,5</sup> and O Youngin Lee <sup>2,5</sup>
```

- Department of Family Medicine, Medical Research Institute and Busan Tobacco Control Center, Pusan National University Hospital, Busan 49241, Korea
- Pusan National University School of Medicine, Yangsan 50612, Korea
- <sup>3</sup> Clinical Trial Center, Department of Biostatistics, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea
- Department of Family Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, Korea
- <sup>5</sup> Family Medicine Clinic, Obesity, Metabolism and Nutrition Center Pusan National University Yangsan Hospital, Yangsan 50612, Korea
- \* Author to whom correspondence should be addressed.







## **APAC Network Presentations**

Thank you to Byungkon Kang and Ty Stanford for their presentations last week on the APAC Community Calls. These videos have been posted to our APAC page (see link below).

Deep-learning-based automated terminology mapping in OMOP-CDM

Byungkon Kang (SUNY Korea), Jisang Yoon, Ha Young Kim (Yonsei Univ.), Sung Jin Jo (POSTECH), Yourim Lee (EvidNet), Hye Jin Kam (Hanwha Life)





www.ohdsi.org/apac





## June Newsletter Is Available



#### Where We've Been


- The OHDSI network study <u>Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study</u> was published May 11 by **The BMJ**. It found substantial heterogeneity over the types of drugs used for COVID-19 treatment purposes globally.
- Another OHDSI network study, 30-day outcomes of Children and Adolescents with COVID-19: An International Experience, was published this month by Pediatrics. Among others, this study characterized the treatments, symptoms and outcomes of interest of more than 242,000 children/adolescents diagnosed and nearly 10,000 hospitalized with COVID-19 across five countries.
- The fourth open data partner call within the EHDEN Consortium ended with 55 applications from across 20 European nations looking to join the expanding EHDEN data network.

#### Where We Are

- Ongoing work in the PIONEER Prostate Cancer Study-A-Thon a collaboration that included both the OHDSI and EHDEN was shared during the May 18 community call. This study investigated the natural history and outcomes of prostate cancer patients managed with watchful waiting, a conservative management option for prostate cancer patients with a life expectancy of less than 10 years at time of diagnosis.
- Leaders from the six regional chapters of the Asia-Pacific region provided exciting updates on OHDSI's growth through Australia, China, Japan, Korea, Singapore and Taiwan.

#### Where We're Going

- The deadline for submissions for the 2021 Collaborator Showcase is June 18. More information is available here, and there was a brief discussion of the submission process during a recent community call.
- The next edition of the CBER BEST Initiative Seminar Series will be Wednesday, June 16, at 11 am. **Bruce Fireman** (Kaiser Permanente) will present a talk on "Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines." The seminar series is open to everybody. More information and a registration link is available here.
- There are five exciting community calls planned for June; these calls are held Tuesdays at 11 am ET, and they are open to everybody. The meeting topics are posted later in this newsletter.



#### **Recent Publications**

Matthew E. Spotnitz, George Hripcsak, Patrick B. Ryan, Karthik Natarajan. Characterizing Post-Acute Sequelae of SARS-CoV-2 Infection across Claims and Electronic Health Record Databases. medRxiv 2021.03.19.21253756; doi: https://doi.org/10.1101/2021.03.19.21253756

Prats-Uribe A, Sena AG, Lai LY, Ahmed W, Alghoul H, Alser O, Alshammari TM, Areia C, Carter W, Casajust P, Dawoud D, Golozar A, Jonnagaddala J, Mehta P, Gong M, Morales DR, Nyberg F, Posada J, Recalde M, Roel E, Shah K, Shah NH, Schilling L, Subbian V, Vizcaya D, Zhang L, Zhang Y, Zhu H, Liu L, Cho J, You SC, Rijnbeek P, Hripcsak G, Lane JCE, Burn E, Reich C, Suchard M, Duarte-Salles T, Kostka K, Ryan PB, Prieto-Alhambra D. <u>Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.</u> BMJ. 373 2021; doi:10.1136/bmj.n1038.

R P Vogelsang, R D Bojesen, E R Hoelmich, A Orhan, F Buzquurz, L Cai, C Grube, J A Zahid, E Allakhverdiiev, H H Raskov, I Drakos, N Derian, P B Ryan, P R Rijnbeek, I Gögenur, Prediction of 90-day mortality after surgery for colorectal cancer using standardized nationwide quality-assurance data, BJS Open, Volume 5, Issue 3, May 2021, zrab023, doi.org/10.1093/bisopen/zrab023

Shin, H., Lee, S. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources. *BMC Med Inform Decis Mak* 21, 159 (2021). doi.org/10.1186/s12911-021-01520-y

Duarte-Salles T, Vizcaya D, Pistillo A, Casajust P, Sena AG, Lai LY, Prats-Uribe A, Ahmed W, Alshammari TM, Alghoul H, Alser O, Burn E, You SC, Areia C, Blacketer C, Duvall S, Falconer T, Carter W, Fernandez-Bertolin S, Fortin S, Golozar A, Gong M, Tan EH, Huser V, Iveli P, Morales DR, Nyberg F, Posada J, Recalde M, Roel E, Schilling L, Shah NH, Shah K, Suchard M, Zhang L, Zhang Y, Williams A, Reich C, Hripcsak G, Rijnbeek P, Ryan PB, Kostka K, Prieto-Alhambra D. 30-day outcomes of children and adolescents with COVID-19: an international experience. Pediatrics. 2021; doi: 10.1542/peds.2020-042929.

#### **Community Call Presentations**

#### May 4: Workgroup Updates

GIS – Geographic Information System (Robert Miller)
PEI – Pharmacovigilance Evidence Investigation (Erica Voss)

UK Biobank/Registry (Maxim Moinat)

Electronic Health Records (Melanie Philofsky)






## June Newsletter Is Available





#### **The Journey Newsletter (June 2021)**

The OHDSI community published two important studies on both the early heterogeneity of COVID-19 patient treatment and 30-day outcomes of children and adolescents diagnosed with COVID-19, and it continues to collaborate in the ongoing PIONEER Prostate Cancer Study. Those updates, as well as information on the upcoming (June 18) deadline for 2021 Collaborator Showcase submissions, are all part of the latest edition of The Journey Newsletter! #JoinTheJourney





## **OHDSI Shoutouts!**



## Any shoutouts from the community? Please share and help promote and celebrate OHDSI work!


Have a study published? Please send to <a href="mailto:sachson@ohdsi.org">sachson@ohdsi.org</a> so we can share during this call and on our social channels. Let's work together to promote the collaborative work happening in OHDSI!





## Three Stages of The Journey

# Where Have We Been? Where Are We Now? Where Are We Going?





## **Upcoming Workgroup Calls**



Date	Time (ET)	Meeting
Wednesday	10 am	OMOP CDM Oncology – Development Subgroup
Wednesday	2 pm	Natural Language Processing
Wednesday	4 pm GMT +9	Early Stage Researchers (East Coast/West Coast/APAC Region)
Thursday	8 am	Psychiatry
Thursday	1 pm	OMOP CDM Oncology – CDM/Vocabulary Subgroup
Friday	10 am	China Chapter
Friday	10 am	Clinical Trials
Friday	10 am	Electronic Health Records
Friday	1 pm	Phenotype Development and Evaluation
Tuesday	9 am	OMOP CDM Oncology – Genomic Subgroup

www.ohdsi.org/upcoming-working-group-calls



## **Get Access To Different Teams/WGs/Chapters**




4. Select the workgroups you want to join (you can refer to the WIKI for work group objectives <a href="https://www.ohdsi.org/web/wiki/doku.php?id=projects:overview">www.ohdsi.org/web/wiki/doku.php?id=projects:overview</a> )				
_ ATLAS				
Clinical Trials				
Common Data Model	Phenotype Development and Evaluation			
Data Quality Dashboard Development	Population-Level Effect Estimation / Patient-Level Prediction			
Early-stage Researchers	Psychiatry			
Education Work Group	Registry (formerly UK Biobank)			
Electronic Health Record (EHR) ETL	Surgery and Perioperative Medicine  Vaccine Vocabulary			
Geographic Information System (GIS)	Women of OHDSI			
HADES Health Analytics Data-to-Evidence Suite				
Latin America	5. Select the chapter(s) you want to join			
Medical Devices	Australia			
Natural Language Processing	☐ China ☐ Europe			
OHDSI APAC	☐ Japan			
OHDSI APAC Steering Committee	☐ Korea			
OHDSI Steering Committee	Singapore			
Oncology	Taiwan			
Patient-Generated Health Data	6 Colort the studies you want to isin			
Pharmacovigiliance Evidence Investigation	6. Select the studies you want to join  HERA-Health Equity Research Assessment			
	PIONEER for Prostate Cancer (study-a-thon ended)			
	SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)			





## **Get Access To Different Teams/WGs/Chapters**



4. Select the workgroups you want to join (you can refer to the WIKI for work group objectives <a href="https://www.ohdsi.org/web/wiki/doku.php?id=projects:overview">www.ohdsi.org/web/wiki/doku.php?id=projects:overview</a> )				
_ ATLAS	] ATLAS			
Clinical Trials				
Common Data Model	Phenotype Development and Evaluation			
Data Quality Dashboard Development	Population-Level Effect Estimation / Patient-Level Prediction			
Early-stage Researchers	Psychiatry			
Education Work Group	Registry (formerly UK Biobank)			
Electronic Health Record (EHR) ETL	Surgery and Perioperative Medicine  Vaccine Vocabulary			
Geographic Information System (GIS)	Women of OHDSI			
HADES Health Analytics Data-to-Evidence Suite				
Latin America	5. Select the chapter(s) you want to join			
Medical Devices	Australia			
Natural Language Processing	China			
OHDSI APAC	Europe			
OHDSI APAC Steering Committee	☐ Japan ☐ Korea			
OHDSI Steering Committee	Singapore			
Oncology	Taiwan			
Patient-Generated Health Data				
	6. Select the studies you want to join			
Pharmacovigiliance Evidence Investigation	HERA-Health Equity Research Assessment			
	PIONEER for Prostate Cancer (study-a-thon ended)			
	SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)			



## **CBER Seminar Series**

The next edition of the CBER BEST Initiative Seminar Series will be Wednesday, June 16 (11 am). Bruce

Fireman (Kaiser Permanente) will present a talk on "Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines." The seminar series is open to everybody. Get more information and the registration link by using the link below.



Webinar Registration



Fopic CBER BEST Initiative Seminar Series - Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines

We review statistical methods used in observational studies of the safety and effectiveness of COVID-19 vaccines. Topics include:

Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines

- How to compare recent vaccinees with concurrent comparators (unvaccinated or less recently vaccinated) and with comparators who are not concurrent (historical rates or self-controls) to make inferences about outcome rates that would be expected among vaccinees had they not been vaccinated.
- Methods for estimating risk ratios
- How to examine change in vaccine effectiveness (waning) or vaccine safety over timesince-vaccination
- Seguential tests

Presented by: Bruce Fireman, MA - Kaiser Permanente



https://northeastern.zoom.us/webinar/register/WN\_94CygX5JTfSyhDSsOYnxqg



## **Job Opportunity**

#### **Associate Director, Epidemiology**

Location Titusville, New Jersey Category R&D Req ID: 2105936215W

#### **Job Description**

Janssen Research & Development, LLC, a member of the Johnson & Johnson Family of Companies, is recruiting for the role of Associate Director in Epidemiology. This role may be on site (Titusville, NJ or Raritan, NJ) or remote.

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at <a href="https://www.janssen.com">www.janssen.com</a> and follow us @JanssenGlobal. Janssen Pharmaceuticals, LLC is part of the Janssen Pharmaceutical Companies.

This position will be focused on supporting the 'Real-World Assessment and Research of Drug Performance' (REWARD) initiative, an ambitious collaborative effort to develop a systematic process for observational database analyses to enable exploration and identification of differentiated benefits of medical products to support R&D's clinical development strategy. You will also perform pharmacoepidemiology activities to support the neuroscience therapeutic area, including characterizing disease natural history and treatment patterns, safety evaluations, benefit- risk assessments, and patient-level prediction models.

Apply

Share Job









## **Collaborator Showcase Abstracts Due June 18**

We are 10 DAYS AWAY from the June 18 deadline for submissions for the 2021 Collaborator Showcase.

We are accepting submissions for posters, oral presentations and software demos.

Home > 2021 OHDSI Collaborator Showcase

#### 2021 OHDSI Collaborator Showcase

Thank you for your interest in the 2021 OHDSI Collaborators Showcase! We are delighted that you are considering joining our research community and presenting your work at this year's virtual symposium showcase.

OHDSI's mission is to improve health by empowering a community to collaboratively generate evidence that promotes better health decisions and better care. We envision a world in which observational research produces a comprehensive understanding of health and disease. To achieve this goal, OHDSI has formed a multi-stakeholder, interdisciplinary collaboration that aims to bring out the value of health data through large-scale analytics and open-source software tools. OHDSI has established a global community of observational health researchers and a research network

OHDSI's achievements to date would not be possible if not for the hard work of our growing community members. Our annual Collaborator Showcase provides our community the opportunity to share their tremendous work. Last year, the OHDSI community produced more than 100 posters/talks/demos for our Collaborator Showcase

Once again, we are inviting collaborators to participate in the Collaborator Showcase for this year's 2021 Global OHDSI Symposium. Collaborators will have the opportunity to submit their work for poster presentations, oral talks, and software demonstrations.

#### Topics of interest include:

- Observational data standards and management
- Methodological research
- Open-source analytics development
- Clinical research from OHDSI's analytic use cases:
- Clinical characterization
- · Population-level estimation
- · Patient-level prediction

#### Go to top

#### SHOWCASE STRUCTURE:

The showcase will be structured to highlight posters, oral talks, and software demonstrations

We are currently working out all the details for the 2021 Global Symposium. Please continue to join our community calls (Tuesdays, 11 am ET), check the forums, MSTeams and the OHDSI website, as well as emails from OHDSI Events manager, to learn more details about an informative and productive showcase this year!



## **Collaborator Showcase Abstracts Due June 18**





## Collaborator Showcase Abstracts Due June 18

#### SUBMISSION INSTRUCTIONS:

A submission template can be found here: Submission Template

The document can be downloaded as a Microsoft Word document by clicking on the link and selecting File->Download As...-> Microsoft Word (.docx).

Each presenting author should upload their document as a PDF. The submission should meet the following guidelines:

- Maximum 1000 words of text (exclusive of references/citations)
- · Clearly state the names of all co-authors and list them in the order that will appear on the presentation (please do not include titles or degree/certificate credentials)
- Have the following components: Title, Background, Methods, Results, Conclusions.
- · References/citations are recommended (maximum 15; suggested style is Vancouver).
- . Unpublished in the peer-review literature at the time of submission; preprints are acceptable
- [Optional] up to 3 additional Figures, tables, and equations can be added to support description of the methods or results

By submitting your work, the presenting author agrees to present at the OHDSI Symposium if their work is selected. Your document should be saved as a PDF using the following naming convention, where the "firstname" and "lastname" correspond to the name of the presenting author, and "title" should include keywords that summarize the title: firstname-lastname title 2021symposium

#### Go to top

#### IMPORTANT DATES:

All submissions are due no later than 8pm (EST) on Friday, June 18, 2021.

All submissions will be peer-reviewed by the OHDSI Scientific Review Committee between June 18-July 26.

If you have been selected to present your work for the 2021 Symposium Collaborators Showcase, you will be notified via email by Monday, August 2, 2021.

Should you need additional assistance, please email us at symposium@ohdsi.org.

#### SUBMISSION UPLOAD:

To submit your research for the 2021 Collaborators Showcase, please click the link below and fill out the form (in order to access the submission form, you need to have a Google Account. If you need to set up a Google Account, please click here: Create a Google Account)

Submission Link

### **OHDSI**

#### 2021 OHDSI Collaborators Showcase Brief Report Submission Form-Posters. Oral Talks and Software Demonstrations

that you are interested in showcasing your work at this year's virtual symposium showcase. For planning purposes, please take a few minutes to fill out this submission form to help the Scientific Review Committee hetter understand your solution

By filling out this form you may choose if you would like to present your work as a poster, an oral talk or a software demonstration (or all three). If a poster or software demo, you v present it during the Collaborator Showcase at the symposium. If an Oral talk, you will

If you wish to present as a poster or an oral talk only, after you complete that question asked to submit a one-page overview of your software. If you want to submit for all three (software demo, poster and/oral talk), it will then ask you to submit a brief report for the poster and/or oral submission.

Although we strive to accommodate your requested presentation format, it is not guaranteed. If the review committee has selected your work to be presented at this year's showcase, you will be notified via email by August 2, 2021 and the presentation format will be confirmed at that time

Topics should align with at least one of OHDSI's strategic areas of focus.

- . Observational data standards and managemen
- Open-source analytics development
   Methodological research
   Clinical applications

#### SUBMISSION INSTRUCTIONS:

sion template can be found by using the below link https://docs.google.com/document/d/1GADPitvH1eXHX\_W9qBOlg-

The document can be downloaded as a Microsoft Word document by clicking on the link and selecting File->Download As...-> Microsoft Word (.docx)

#### Title of Your Brief Report Submission

Please list all authors in the correct order and do not include titles or certificate/degree credentials (correct example: First name Last name, First name Last name, First name Last name, etc.)

This template should be used as a starting point for the submission. It should be a background of your understanding of the current state of the literature / science as it relates to the topic you are spotlighting in this brief report. This report should be on something that is unpublished in the literature. If you have a preprint on the topic and it is still not accepted in a peer-reviewed publication, we welcome the content for submission as well. Make sure to include a few citations in here of other people's work. This sentence has two reference citations.1

This section should talk about the methods supporting your brief submission. Methods can be interpreted as both statistical methods. It can also be the reproducible, repeatable process you followed to generate the brief report content you are writing about.

More text of an additional paragraph, with a figure reference (Figure 1) and a figure inside a Word text box below. Figures need to be placed as close to the corresponding text as possible and not extend beyond one page. Use a minimum of 9pt font for Figure captions, You can include up to 3 figures in your submission (these are optional though highly encouraged).



Figure 1. Total allergy alerts, overridden alerts, or drug order cancelled

This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting.



## Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?





## Three Stages of The Journey

# Where Have We Been? Where Are We Now? Where Are We Going?





## **APAC 10-Minute Tutorials**



White Rabbit



**USAGI**Seng Chan You

**Xialin Wang** 



**Data Quality Dashboard** 

Selva Muthu Kumaran Sathappan

#### **OHDSI APAC - Our Asia-Pacific Community**

OHDSI is a global, multi-stakeholder, interdisciplinary and openscience network that collaborates to bring out the value of health data through large-scale analytics. Our Asia-Pacific (APAC) community comprises six regional chapters (Australia, China, Japan, Singapore, South Korea, Taiwan) and has led important OHDSI initiatives around the world.

The first OHDSI APAC Symposium was held virtually Dec. 5-6, 2020, and it provided an opportunity for our Asia-Pacific collaborators (along with others around the world) to share research, provide community updates, collaborate in regional breakouts or network discussions, and have some OHDSI fun.



The APAC community has its own group in the OHDSI MS Teams environment to promote greater collaboration on our collaborative efforts. It will also be the home of our bi-weekly APAC Community Calls, where we will provide updates, share research presentations, collaborate on topics of shared interest, and plenty more. How can you get involved? First, request access to our MS Teams Environment, then request access to our OHDSI APAC workgroup. You can also join the meetings by using this direct link.

Our calls are scheduled on a bi-weekly basis, held every other Thursday/Wednesday depending on where you live. All calls are recorded, so if you miss one or want to share with a collaborator, check out the call recordings below.



www.ohdsi.org/apac/



## **Today's Topic: 10-Minute Tutorials**



PHOEBE
Anna Ostropolets
PhD Student, Columbia University Dept. of Biomedical Informatics



Cohort Diagnostics
Gowtham Rao
Senior Director, Johnson & Johnson



ATC Hierarchy
Christian Reich
VP Real World Analytics Solutions, IQVIA